ConductScience.org, home

Paper39745587

Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report.

Rigamonti A and 3 others. Neurol Sci, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report. Papers, record 39745587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39745587

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report.
PubMed
Journal
Neurol Sci
PubMed
Year
2025
PubMed
Publication types
Letter
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rigamonti AAndreahttps://orcid.org/0000-0002-7393-4205
2Mantero VVittorio
3Milani RRiccardo
4Salmaggi AAndrea

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118642357Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.Muscle Nerve2008https://conductscience.org/library/papers/18642357PubMed
238108913Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.Neurol Sci2024https://conductscience.org/library/papers/38108913PubMed
337389303Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.Brain Commun2023https://conductscience.org/library/papers/37389303PubMed
429066163
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Lancet Neurol2017https://conductscience.org/library/papers/29066163PubMed
520439845The MG Composite: A valid and reliable outcome measure for myasthenia gravis.Neurology2010https://conductscience.org/library/papers/20439845PubMed
636924454Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis.Ann Clin Transl Neurol2023https://conductscience.org/library/papers/36924454PubMed
734378270Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.Oncologist2021https://conductscience.org/library/papers/34378270PubMed
831092901Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.Nat Rev Clin Oncol2019https://conductscience.org/library/papers/31092901PubMed
930078154Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.Curr Neurol Neurosci Rep2018https://conductscience.org/library/papers/30078154PubMed
1036614930Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series.J Clin Med2022https://conductscience.org/library/papers/36614930PubMed
1138205840Novel uses of complement inhibitors in myasthenia gravis-Two case reports.Muscle Nerve2024https://conductscience.org/library/papers/38205840PubMed
1222006686MG-ADL: still a relevant outcome measure.Muscle Nerve2011https://conductscience.org/library/papers/22006686PubMed
1337884388Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.Neurol Neuroimmunol Neuroinflamm2024https://conductscience.org/library/papers/37884388PubMed
1428821685Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.Neurology2017https://conductscience.org/library/papers/28821685PubMed
1510921745Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.Ann Thorac Surg2000https://conductscience.org/library/papers/10921745PubMed
1635438755Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.JAMA Netw Open2022https://conductscience.org/library/papers/35438755PubMed
1732765397Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.Front Neurol2020https://conductscience.org/library/papers/32765397PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42840483Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series.Exp Ther Med2026https://conductscience.org/library/papers/42840483PubMed
41857416Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurol Sci2026https://conductscience.org/library/papers/41857416PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39745587

GET https://conductscience.org/api/papers/v1/39745587/authors